Plasma lipid peroxidation in sporadic Parkinson s disease. Role of the l-dopa
|
|
- Daisy Ford
- 5 years ago
- Views:
Transcription
1 Journal of the Neurological Sciences 240 (2006) Plasma lipid peroxidation in sporadic Parkinson s disease. Role of the l-dopa Ahmad Agil a, Raquel Durán b, Francisco Barrero c, Blas Morales c, Mariano Araúzo d, Francisco Alba e, Ma Teresa Miranda f, Isabel Prieto g, Manuel Ramírez g, Francisco Vives b, * a Department of Pharmacology and Institute of Neurosciences of Granada, Spain b Department of Physiology and Institute of Neurosciences of Granada, Faculty of Medicine, Avda. Madrid, 11, Granada, Spain c Motor Disease Unit, Hospital Clínico San Cecilio, Granada, Spain d Clinical Biochemistry, Hospital Clínico San Cecilio, Granada, Spain e Department of Biochemistry and Institute of Neurosciences, Spain f Department of Biostatistics. Faculty of Medicine, University of Granada, Avenida de Madrid 11, E Granada, Spain g Unit of Physiology, University of Jaén, Spain Received 1 March 2005; received in revised form 18 August 2005; accepted 29 August 2005 Available online 10 October 2005 Abstract Oxidative stress plays an important role in the pathogenesis of neurodegenerative diseases, such as Parkinson s disease (PD). There are several methods to measure oxidative stress, being lipid peroxidation (LPO) one of the most frequently used. Endogenous plasma LPO was determined by a spectrofluorimetric method in fifty two patients with sporadic PD and in forty controls. To know the maximum capacity of lipids to peroxidate, LPO was also measured after co-incubation with Fe 2+ /H 2 O 2 (exogenous LPO). All PD patients were taken l-dopa and the effect of this treatment on LPO levels was additionally studied. Urine catecholamines and their main metabolites were also analyzed, and their possible correlation to LPO statistically studied. Endogenous plasma LPO levels were 33% higher in PD group than in control group ( P <0.001). Exogenous plasma or oxidizability was also higher in PD patients compared to controls (20%, P <0.05). The intake of l-dopa was negatively dose-related to endogenous and exogenous plasma LPO. In conclusion, plasma of PD patients has elevated levels of LPO and also is more prone to peroxidation than that in the control group. The results also suggest an antioxidant effect of l-dopa. D 2005 Elsevier B.V. All rights reserved. Keywords: Parkinson s disease; Oxidative stress; l-dopa; Catecholamines; Lipid peroxidation 1. Introduction Oxidative stress is believed to be involved in the pathogenesis of various diseases including atherosclerosis, diabetes mellitus, epilepsy, inflammatory and neurodegenerative diseases, and cancer [1 5]. The increase of free radicals produces lipid peroxidation, one of the major causes of cell membrane damage that eventually leads to degeneration of cells [4]. * Corresponding author. Tel.: ; fax: address: fvives@ugr.es (F. Vives). Parkinson s disease (PD) is a common disabling neurodegenerative and progressive disorder characterized by rigidity, tremor, and motor disturbances. The pathogenesis of PD is not completely understood, but oxidative stress seems to be one of the main etiological factors [6]. In PD, the pathological death of dopaminergic neurons in the substantia nigra (SN) pars compacta leads to less availability of dopamine in the striatum. Since the oxidative metabolism of dopamine generates cytotoxic free radicals, neurons of SN are particularly vulnerable to oxidative stress. Dopamine can be oxidized by either monoamine oxidase or undergo autooxidation to generate hydrogen peroxide [7]. H 2 O 2 can damage the neuron directly or indirectly through the X/$ - see front matter D 2005 Elsevier B.V. All rights reserved. doi: /j.jns
2 32 A. Agil et al. / Journal of the Neurological Sciences 240 (2006) formation of hydroxyl radicals in presence of ferrous ions by the Fenton reaction [8,9]. Not only dopamine, but also the dopamine metabolite neuromelanin, found within the SN neurons, promotes site-specific accumulation of iron, thereby potentiating iron-induced LPO, and consequently cell death [10,11]. Thus, free radicals are one of the most important agents responsible of SN neuronal degeneration. Although the role of peroxidation in SN is well established, the significance of peripheral oxidative stress in PD is still unclear and the results are apparently contradictories. While some studies showed an increase of oxidative stress [12,13], other authors described no changes [14]. Differences in the results may be due to differences in the methods used to measure systemic oxidative stress. We have previously suggested that the oxidation of LDLlipoprotein and/or erythrocytes may be an indicative of systemic oxidative stress [9,15]. However, these studies provide only a limited picture, because these approaches fail to evaluate the roles of pro-oxidants and anti-oxidants factors in plasma which play an important role on the oxidative stress regulation. Plasma oxidation may be more biologically relevant than other such as LDL and/or erythrocyte s oxidation since water-soluble antioxidants such as ascorbic acid, uric acid and other plasma constituents would also be taken into account. In addition, l-dopa is one of the most used drug in the treatment of PD. In the CNS, l-dopa is quickly transformed in dopamine and both may be relevant in oxidative stress. The importance of l-dopa on systemic oxidative stress in PD patients remains unresolved. Peripheral oxidation status in PD might be affected by the possible effect of l-dopa treatment. l-dopa seems to exert toxic effects on cultured dopaminergic neurons [16]. However, there is no evidence from in vivo studies suggesting that l-dopa treatment damages SN neurons in PD. On the other hand, while Martignoni et al. [17] have showed that l-dopa therapy increased the concentration of 2,3 dihydroxybenzoate in platelets of PD patients, other studies have described no correlation between the dose of l-dopa and basal plasma oxidative status measured as % CoQ-10 [18], serum malonildialdehyde [19], or blood hydroxyl radicals and plasma [14]. The aim of this study was to evaluate the oxidative stress and the susceptibility of plasma oxidation in PD patients. Additionally, the possible correlation among l-dopa, catecholamines and its main metabolites and the oxidative status in PD was also studied. 2. Materials and methods Fifty two patients were diagnosed of sporadic PD (PD group). All patients were under treatment in the Alteration Movement Unit of the University Hospital of Granada, Spain. The control group consisted of a randomized group of forty subjects, showing acute or chronic osteoarticular pathology, with similar distribution of age and sex. All of them were examined and questioned by an experienced neurologist to rule out signs and symptoms suggestive of early PD, and they had no known relatives with PD. On the other hand, PD was diagnosed by at least two neurologists, following the criteria of the Brain Bank of the Society of Parkinson s disease of United Kingdom [20]. To assess PD patients a clinic interview, demographic data, clinical history (evolution time, symptoms, half of the body more affected at the beginning), step of PD (Hoehn and Yahr score) [21], and UPDRS (Unified Parkinson s Disease Rating Scale) [22] were used. This study was approved by the Ethical Committee for Human Research of the University Hospital of Granada. All PD patients were taken l-dopa and the duration of PD was 87.88T8.16 months since diagnosis. The Hoehn and Yahr stage were: stage 1, 6 patients; stage 2, 19 patients; stage 3, 21 patients; stage 4, 5 patients and stage 5, 1 patient. The UPDRS values were: UPDRS (I) =3.58T 0.38; UPDRS (II)=14.26T1.44 and UPDRS (III)=23.32T 1.76 (meants.e.m.) Analysis of catecholamines After column extraction, concentrations of noradrenaline, adrenaline, dopamine, vanil mandelic acid, 5-hydroxyindol acetic acid, and homovanillic acid in urine collected during 24 h were determined by HPLC with electrochemical detection by commercially available kits (N.S. Lab, S.L., Seville, Spain) Determination of plasma lipid peroxides To determinate lipid peroxide concentration, plasma was collected in tubes containing EDTA as an anticoagulant and stored at 80 -C until analysis. Cholesterol and triglycerides were measured. Lipid peroxides were determined in duplicate both in the basal state and after co-incubation with hydrogen peroxide and ferrous salt to generate hydroxyl radicals by the Fenton reaction. A modification of the assay of Yagi [23] was used. Three modifications were made to improve the specificity of the plasma LPO measurement. First, water-soluble substances, which also react with TBA to yield the same product as LPO, were removed by including a phosphotungstic acid/sulfuric acid step to precipitate lipids with proteins. Second, interference from bilirubin was prevented by reading the fluorescence at 553 nm rather than at 532. Finally, sialic acid interference was eliminated by adding acetic in the TBA reagent. The detailed method has been published elsewhere [9]. The results obtained with this method have been shown to correlate strongly with high-pressure liquid chromatography methods for the determination of LPO levels (r = 0.85). The intra-assay and inter-assay coefficients of variation for measured lipid peroxide concentrations were 4.0% and 4.2%, respectively, in our laboratory.
3 A. Agil et al. / Journal of the Neurological Sciences 240 (2006) Table 1 Medication regime of PD patients Drug (n) Dose (mg/day) l-dopa (52) T39.35 Pramipexole (18) 1.31T0.85 Entacapone (11) T Selegiline (11) 8.64T2.33 Pergolide (10) 2.04T1.05 Ropinirole (5) 9.00T8.48 Bromocriptine (2) 10.00T7.07 Lisuride (1) 0.40T0.00 Amitriptyline (5) 12.50T0.00 Nortriptyline (1) 12.50T0.00 Maprotyline (1) 10.00T0.00 All PD patients were taking l-dopa together with the medication indicated in the table. Values represent meants.e.m. n =number of subjects taken medication Statistical analysis Statistical analysis was performed using one way ANOVA followed by Bonferroni, Games-Howell, or Dunnet t test where appropriate. Correlations between l-dopa and LPO end or LPO exo were analyzed by Pearson correlation. Table 3 Concentrations of noradrenalin, adrenalin, dopamine, vanil mandelic acid, 5-hydroxyindol acetic acid, and homovanillic acid in urine collected during 24 h Controls (n =17) PD (n =31) Noradrenaline (Ag/L) 25.90T T4.08 ns Adrenaline (Ag/L) 3.03T T4.05 ns Dopamine (Ag/L) T ,114.91T *** Vanil mandelic (mg/l) 2.46T T0.41*** HIAA (mg/l) 3.08T T0.52* HVA (mg/l) 2.46T T3.42*** MeanTS.E.M. of two separate experiments. ns: not significant; *P <0.05; ***P < Statistical analysis was performed using one way ANOVA, followed by Bonferroni and Games Howell tests. between 1.23 and 6.83 Amol/L and LPO exo between 2.27 and 7.96 Amol/L. Table 3 shows the concentrations of noradrenalin, adrenalin, dopamine, vanil mandelic acid, 5-hydroxyindol acetic acid, and homovanillic acid in urine collected for 24 h. Except noradrenalin and adrenaline, all other catecholamine and metabolites increased significantly in PD group, 3. Results There were not significant differences in age and sex between groups. Both, control and PD groups were normolipemic: control group, cholesterol T6.00 mg/100 ml and triglycerides 179 T10.38 mg/100 ml; PD group, cholesterol T 6.48 mg/100 ml and triglycerides T 9.73 mg/100 ml. Although all these values were in the range of normality, control group had cholesterol levels lower than in the PD group ( P <0.001) and triglycerides higher than in the PD group ( P <0.001). Table 1 shows medication regime of PD patients. All PD patients were taken l-dopa together to the medication indicated in the table. Table 2 shows plasma concentrations of LPO in basal conditions and in presence of FeSO 4 and H 2 O 2.In both cases, LPO concentrations were significantly higher in the PD group (LPO end : control 2.80T0.12; PD, 3.19T0.16 Amol/L, P<0.001; LPO exo : control, 3.90T0.17; PD: 4.70 T 0.28 Amol/L, P < 0.05). Range of values: control group, LPO end minimum, 0.83 and maximum 4.67 Amol/L; LPO exo between 1.74 and 6.5 Amol/L; PD group, LPO end Table 2 Plasma concentration of lipid peroxides (LPO) in controls and PD patients Controls (n =40) PD (n =52) LPO end (Amol/L) 2.80T T0.16*** LPO exo (Amol/L) 3.90T T0.28* LPO end : Plasma LPO in absence of FeSO 4 and H 2 O 2. LPO exo : Plasma LPO in presence of FeSO 4 and H 2 O 2. MeanTS.E.M. of two separate experiments. ns: not significant; *P <0.05; ***P < Statistical analysis was performed using one way ANOVA followed by Bonferroni and bilateral Dunnet t test. Fig. 1. Linear regression showing the negative relationship between l-dopa dose (mg/day) and LPO end (A) and LPO exo (B). Graphics shows mean prediction with 95% of confidence (curves) and individual prediction interval, also with 95% of confidence.
4 34 A. Agil et al. / Journal of the Neurological Sciences 240 (2006) composed of patients taken l-dopa at dose individually adjusted. The highest increase was observed in plasma dopamine. The correlation between antiparkinsonian medication, catecholamines and their metabolites and LPO end and LPO exo was also assessed. l-dopa was negatively correlated to LPO end ( P <0.01) and LPO exo ( P <0.01) (Fig. 1A and B). Dopamine and adrenaline were also negatively correlated to LPO end ( P <0.01 and P <0.05, respectively) and LPO exo ( P <0.01 and 0.05, respectively). Homovanillic acid was negatively correlated to LPO end ( P <0.05). 4. Discussion In the present study, we found raised endogenous plasma LPO concentrations (13.9%, P < 0.001) (Table 2) in PD patients, suggesting that they are chronically under systemic oxidative stress. These findings are in agreement with other studies in PD, showing increases in systemic oxidative stress, measured in plasma as LPO levels [12,13]; conjugated dienes [24] and coenzyme Q10 oxidized [18]. On the contrary, other study reported no significant changes in serum level of malonildialdehyde (MDA) in PD patients [14]. In our study, we also measured plasma susceptibility to lipid peroxidation, that provides a complete picture about the entire oxidative stress status of plasma from PD patients [25]. The present data show by the first time, an increase in PD plasma susceptibility to lipid peroxidation through hydroxyl radical by the addition of Fe 2+ /H 2 O 2 system, compared to plasma of controls (20.5%, P < 0.05). Therefore the plasma of PD patients is more prone to lipid peroxidation than that of controls. The PD patients used in this study were in different stages of the disease. There was not correlation between the stage of the disease and LPO. This lack of correlation may be due to clinical symptoms appears when PD is advanced and most of 70% of dopaminergic neurons in SN are died. Plasma concentrations of LPO may be affected by lipids as cholesterol and triglycerides. Control and PD groups were normolipemic, and cholesterol and triglycerides concentrations were in the range of normality. However, statistical analysis showed that in the PD group triglyceride concentrations were lower than in the control group ( P < 0.001). Lower concentrations of triglycerides in PD have been recently reported by Buhmann et al. [24]. The same authors found increased oxidative stress in PD patients despite they had similar levels of cholesterol than controls. Thus, although we found higher concentrations of cholesterol in the PD group, other factors may influence oxidative stress. PD may be consider as a systemic disorder because defects in mitochondrial oxidative phosphorilation mostly due to low mitochondrial oxidative complex I activity were observed not only in the substantia nigra but also in peripheral tissues [18]. Our hypothesis is that the increase of oxidative stress at peripheral level parallels with oxidative processes in the CNS. Within SN, the environment leads to the formation of free radicals that react instantaneously with membrane lipids and cause lipid peroxidation and cell death [26]. Some authors have shown an enhanced lipid peroxidation in SN of post-mortem brain in PD [27 29] Brain tissue extracts of PD patients showed a ten-fold increase in lipid hydroperoxides in SN compared to control subjects [30]. Alsoin experimental animals, MPTP (a neurotoxin able to produce parkinsonism) produced a significant increase of LPO in SN [27]. Thus, oxidative stress is present in PD both at central and peripheral levels, but our data do not permit to conclude if there is any relationship between these two compartments. Other question is whether l-dopa has any influence on the oxidative status. Under medication, the presence of drugs and their metabolites may act as pro-oxidant or anti-oxidant in plasma [3]. The balance among these factors should, in turn, determine oxidative stress on PD. In our study, all PD patients were under l-dopa treatment, and this drug might be responsible for changes in plasma oxidation ex-vivo. Despite that in vitro studies have demonstrated the potential of l-dopa to exert toxic effects on cultured dopaminergic neurons [16], there is little or no evidence from in vivo models suggesting that l-dopa treatment damage nigral neurons in PD [31]. Therefore, it is believed that l-dopa may increase free radicals generation by increasing dopamine oxidation and thus, facilitating PD progression. It is possible that l-dopa treatment (by itself or by their metabolites) may also affects peripheral endogenous and/or exogenous LPO levels. Our results show that the intake of l-dopa correlates negatively with LPO end in a dose-dependent way ( y = x; r =0.51, P < 0.01 ) (Fig. 1A) and moreover, we also found a negative correlation between l-dopa and LPO exo (Fig. 1B). These results, obtained through the ex vivo model system [9], may indicate that l-dopa can act as antioxidant in plasma and thus ameliorate PD progression. Several studies described a non significant correlation between l-dopa dose and basal oxidative status, measured as plasma % CoQ-10 [18], serum MDA [19], blood hydroxyl radicals and plasma SOD [14]. Except in the case of l-dopa, we did not find any significant correlation between LPO and medication regime. Experimentally, selegiline (deprenyl) showed antioxidant properties. Although it may have anti-oxidant effects in PD patients, the low number (11) of patients that were taken selegiline in this study did not permit to find out any difference. Like l-dopa, dopamine or others catecholamine metabolites can affect oxidative stress under experimental conditions. We found elevated concentrations of dopamine, vanil mandelic acid, 5-hydroxyindol acetic acid, and homovanillic acid in urine of PD patients, being dopamine levels the highest. Only dopamine and adrenalin levels were negatively correlated to LPO end ( y = x ; r =0.40, P <0.05;
5 A. Agil et al. / Journal of the Neurological Sciences 240 (2006) y = x; r =0.48, P < 0.01, respectively). Our findings agree with those of Scigliano et al. [32] who showed an increase of plasma bilirubin, a potent antioxidant [33] in PD patients under l-dopa treatment compared to untreated parkinsonians and controls. In opposition, other authors have suggested a potential prooxidative role of l-dopa [24]. Therefore, the present results could indicate that l-dopa, dopamine and adrenalin may act as antioxidants in plasma, and thus they might ameliorate peripheral collateral effects that accompanies PD progression. In contrast to others investigations, our study measured plasma susceptibility to an exogenous OH, which actually reflects the resistance of plasma toward oxidation and therefore provides information about the entire oxidative status of plasma in PD patients. As a result, l-dopa treatment can lead to a decreased systemic free radicals generation associated to this process and subsequently, to diminish plasma endogenous and exogenous LPO levels. These findings point out that there is a reduction in the concentrations of plasma LPO in PD patients treated with l-dopa in a dose-related manner. Taken together the above mentioned data, it can be concluded that plasma from PD patients is under oxidative stress as evidenced by increased basal LPO. Our results support the involvement of systemic oxidative stress in pathogenesis of PD and provide additional information about the role of systemic l-dopa as antioxidant. We suggest that the progressive impairment of PD that has been related to l-dopa treatment is not mediated by oxidative processes, at least at peripheral level. Acknowledgements This study was supported by grants from the Junta de Andalucía, Spain (CTS 438 and CVI 221). References [1] Plachta H, Bartnikowska E, Obara A. Lipid peroxides in blood from patients with atherosclerosis of coronary and peripheral arteries. Clin Chim Acta 1992;211: [2] Haffner S, Agil A, Miettinen H, Stern M, Jialal I. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose, tolerance and NIDMM. Diabetes Care 1995;18: [3] Martinez-Ballesteros C, Pita-Calandre E, Sanchez-Gonzalez Y, Rodriguez-Lopez CM, Agil A. Lipid peroxidation in adult epileptic patients treated with valproic acid. Rev Neurol 2004;38: [4] Agil A, Miro M, Jimenez J, Aneiros J, Caracuel MD, Garcia-Granados A, et al. Isolation of ani-hepatotoxic principle form the juice of Ecballium elaterium. Planta Med 1999;65: [5] Sundstrom H, Korpela H, Viinikka L, Kauppila A. Serum selenium and glutation peroxidase, and plasma lipid peroxides in uterine, ovarian or vulvar cancer, and their responses to antioxidants in patients with ovarian cancer. Cancer Lett 1984;24:1 10. [6] Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson s disease. Neurology 1996;47:S [7] Khaldy H, Escames G, Leon J, Vives F, Luna JD, Acuna-Castroviejo D. Comparative effects of melatonin l-deprenyl, trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000;29: [8] Cohen G. Oxygen radicals and Parkinson s disease. Proceedings of Upjohn symposium. Bethesda, MD Fed amer soc exp biol; p [9] Agil A, Fuller CJ, Jialal I. Susceptibility of plasma to ferrous iron/hydrogen peroxide-mediated oxidation: demonstration of a possible Fenton reaction. Clin Chem 1995;41: [10] Youdim MB, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson s disease. Mov Disord 1993;8:1 12. [11] Youdim MB, Riederer P. Understanding Parkinson s disease. Sci Am 1997;276:52 9. [12] Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in the novo Parkinson s disease patients. Func Neurol 1999;14: [13] Serra JA, Dominguez RO, de Lustig ES, Guareschi EM, Famulari AL, Bartolome EL, et al. Parkinson s disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson s Alzheimer s and vascular dementia patients. J Neurol Transm 2001;108: [14] Ahlskog JE, Uitti RJ, Lw PA, Tyce GM, Nickander KK, Petersen RC, et al. No evidence for systemic oxidant stress in Parkinson s or Alzheimer s disease. Mov Disord 1995;10: [15] Montilla MP, Agil A, Navarro MC, Jimenez MI, Garcia-Granados A, Parra A, et al. Antioxidant activity of maslinic acid, a triterpene derivative obtained from Olea europaea. Planta Med 2003;69: [16] Mytilineou C, Han SK, Cohen G. Toxic and protective effects of l-dopa on mesencephalic cell cultures. J Neurochem 1993;61: [17] Martignoni E, Blandini F, Godi L, Desideri S, Pacchetti C, Mancini F, et al. Peripheral markers of oxidative stress in Parkinson s disease. The role of l-dopa. Free Radic Biol Med 1999;27: [18] Sohmiya M, Tanaka M, Wei Tak N, Yanagisawa M, Tanino Y, Suzuki Y, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson s disease. J Neurol Sci 2004;223: [19] Ihara Y, Chuda M, Kuroda S, Hayabara T. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson s disease: relationship to clinical data. J Neurol Sci 1999;170:90 5. [20] Gelb DJ, Oliver E, Gliman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33 9. [21] Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17: [22] Fahn S, Elton RL. Unified Parkinson s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein MRecent developments in Parkinson s disease, vol 2. Florham Park, NJ Macmillan; p [23] Yagi K. Assay for blood plasma or serum. Methods Enzymol 1984; 105: [24] Buhmann C, Arlt S, Kontush A, Moller-Bertram T, Sperber S, Oechsner M, et al. Plasma and CSF markers of oxidative stress are increased in Parkinson s disease and influenced by antiparkinsonian medication. Neurobiol Dis 2004;15: [25] Agil A, Sadrzadeh SM. Hydroxy-urea protects erythrocytes against oxidative damage. Redox Rep 2000;5: [26] Omaye ST, Turnbull JD, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues and fluids. Methods Enzymol 1979;62:3 11. [27] Menon NK, Furdik JV, Mishra K. Role of oxygen free radicals in neurological disorders. Adv Clin Neurosci 1994;4: [28] Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson s disease and incidental Lewy body disease. The royal kings and queens Parkinson s disease research group. Ann Neurol 1992;32:S82 7.
6 36 A. Agil et al. / Journal of the Neurological Sciences 240 (2006) [29] Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson s disease. Neurology 1992;42: [30] Marzatico F, Café C, Taborelli M, Benzi G. Experimental Parkinson s disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Neurochem Res 1993;18: [31] Olanow CW. The scientific basis for the current treatment of Parkinson s disease. Annu Rev Med 2004;55: [32] Scigliano G, Musicco M, Soliveri P, Girotti F, Giovannini P, Fetoni V, et al. Increased plasma bilirubin in Parkinson patients on l-dopa: evidence against the free radical hypothesis? Ital J Neurol Sci 1997;18(2): [33] Frei B, Stoker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A 1988;85:
Serum levels of coenzyme Q 10 in patients with Parkinson s disease
J Neural Transm (2000) 107: 177 181 Serum levels of coenzyme Q 10 in patients with Parkinson s disease F. J. Jiménez-Jiménez 1, J. A. Molina 2, F. de Bustos 3, A. García-Redondo 3, C. Gómez-Escalonilla
More informationSuperoxide dismutase activity and zinc and copper concentrations in Parkinson s disease
Pathophysiology 7 (2000) 63 67 www.elsevier.com/locate/pathophys Superoxide dismutase activity and zinc and copper concentrations in Parkinson s disease Pelin Aribal Kocatürk a, *, M. Cenk Akbostanci b,
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationInvestigating molecular mechanisms of progression of Parkinson s Disease in human brain
Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4
More informationFreezing of gait in patients with advanced Parkinson s disease
J Neural Transm (2001) 108: 53 61 Freezing of gait in patients with advanced Parkinson s disease N. Giladi, T. A. Treves, E. S. Simon, H. Shabtai, Y. Orlov, B. Kandinov, D. Paleacu, and A. D. Korczyn Movement
More informationMeasurement of plasma hydroperoxide concentration by FOX-1 assay in conjunction with triphenylphosphine
Clinica Chimica Acta 337 (2003) 147 152 www.elsevier.com/locate/clinchim Measurement of plasma hydroperoxide concentration by FOX-1 assay in conjunction with triphenylphosphine Dibyajyoti Banerjee*, U.K.
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationThe Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.
Kobe J. Med. Sci., Vol. 56, No. 5, pp. E214-E219, 2010 The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. NAOKO YASUI 1, KENJI SEKIGUCHI 1, HIROTOSHI HAMAGUCHI 1, and FUMIO KANDA
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationSUMMARY AND CONCLUSION
SUMMARY AND CONCLUSION 7. SUMMARY AND CONCLUSION Oxidative stress has been repetitively hallmarks of many diseases linked with metabolic or vascular disorders. Diabetes mellitus is the most rapidly growing
More informationOxiSelect Hydrogen Peroxide Assay Kit (Colorimetric)
Product Manual OxiSelect Hydrogen Peroxide Assay Kit (Colorimetric) Catalog Number STA-343 5 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Oxidative stress is a physiological
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationThe levels of oxidative stress and antioxidants in diabetes mellitus before and after diabetic treatment with or without antioxidants
Original article: The levels of oxidative stress and antioxidants in diabetes mellitus before and after diabetic treatment with or without antioxidants *Sarita A Shinde, Anita D. Deshmukh, Adinath N. Suryakar,
More informationSwitching from pergolide to pramipexole in patients with Parkinson s disease
J Neural Transm (2001) Switching 108: 63 70 from pergolide to pramipexole in PD 63 Switching from pergolide to pramipexole in patients with Parkinson s disease P. A. Hanna 1,2, L. Ratkos 2, W. G. Ondo
More informationThe Effect of High Dose IV Vitamin C on Plasma Antioxidant Capacity and Level of Oxidative Stress in Cancer Patients and Healthy Subjects
The Effect of High Dose IV Vitamin C on Plasma Antioxidant Capacity and Level of Oxidative Stress in Cancer Patients and Healthy Subjects N.A Mikirova, Ph.D.; J.A. Jackson, Ph.D., MT(ASCP); Neil H Riordan,
More informationnumber Done by Corrected by Doctor
number 19 Done by حسام ابو عوض Corrected by وسيم ابو عبيدة Doctor د.نايف 1 P a g e GAGs and Glycoproteins: GAGs: long, unbranched heteropolysaccharides, made from زunits repeating disaccharide [Acidic
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationThe Effect of Weighted Compression Sleeves on Tremor Suppression in Individuals with Parkinson s Disease
The Effect of Weighted Compression Sleeves on Tremor Suppression in Individuals with Parkinson s Disease Jennifer Iannello, Garry Johnson, Lauren Pilla Parkinson s Disease Second most common chronic, progressive,
More informationL ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino
L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino Ecografia cerebrale: l accuratezza diagnostica. Lo studio NOBIS Dr Patrizio Prati Neurologia CIDIMU Torinorin Normal
More informationIncreased bilirubin levels in de novo Parkinson s disease
ORIGINAL ARTICLE Increased bilirubin levels in de novo Parkinson s disease M. Moccia a, M. Picillo b, R. Erro c,d, K. Longo e, M. Amboni e, G. Santangelo f, R. Palladino g,h, R. Allocca a, O. Caporale
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationP ISSN: X, E ISSN :
Original article: Determination of reference limit and evaluation of precision to measure Total Antioxidant Capacity (TAC) by Ferric Reducing Antioxidant Power (FRAP) method *Soma Gupta 1, Sanjoy Kunti
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationThis student paper was written as an assignment in the graduate course
77:222 Spring 2003 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2003) offered
More informationSuperoxide Dismutase Kit
Superoxide Dismutase Kit Catalog Number: 7500-100-K Reagent kit for the analysis of Superoxide Dismutase in cell extracts. Sufficient reagents for 100 experimental tests, 50 negative controls, and 50 positive
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More information1 Introduction Imprecision Within-run imprecision, results Day-to-day imprecision, results... 2
Design Verification liquicolor 1 Introduction... 2 2 Imprecision... 2 2.1 Within-run imprecision, results... 2 2.2 Day-to-day imprecision, results... 2 3 Linearity and Detection Limit... 2 3.1 Linearity...
More informationReevaluation of levodopa therapy for the treatment of advanced Parkinson s disease
Parkinsonism and Related Disorders 15, Supplement 1 (2009) S25 S30 www.elsevier.com/locate/parkreldis Reevaluation of levodopa therapy for the treatment of advanced Parkinson s disease Masayuki Yokochi
More informationREVIEW ENDOGENOUS RISK FACTORS IN PARKINSON S DISEASE: DOPAMINE AND TETRAHYDROISOQUINOLINES 1. Lucyna Antkiewicz-Michaluk
Copyright 2002 by Institute of Pharmacology Polish Academy of Sciences Polish Journal of Pharmacology Pol. J. Pharmacol., 2002, 54, 567 572 ISSN 1230-6002 REVIEW ENDOGENOUS RISK FACTORS IN PARKINSON S
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationMyBioSource.com. OxiSelect Ferric Reducing Antioxidant Power (FRAP) Assay Kit. Product Manual. Catalog Number
Product Manual OxiSelect Ferric Reducing Antioxidant Power (FRAP) Assay Kit Catalog Number Introduction Oxidative stress is a physiological condition where there is an imbalance between concentrations
More informationSafinamide: un farmaco innovativo con un duplice meccanismo d azione
Safinamide: un farmaco innovativo con un duplice meccanismo d azione AINAT Sardegna Cagliari, 26 novembre 2016 Carlo Cattaneo Corporate Medical Advisor CNS & Rare Diseases Reichmann H. et al., European
More informationStatus of LDL Oxidation and antioxidant potential of LDL in Type II Diabetes Mellitus
Biomedical Research 2010; 21 (4): 416-418 Status of LDL Oxidation and antioxidant potential of LDL in Type II Singh N, Singh N, Singh S K, Singh A K, Bhargava V. Department of Biochemistry, G. R. Medical
More informationClinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.
UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,
More informationVisualization and Quantification of the Striato pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging
Visualization and Quantification of the Striato pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging Yu Zhang, Katherine Wu, Shannon Buckley, Norbert Schuff On behalf of the Parkinson
More informationTreatment of Parkinson disease has improved dramatically over the past quarter of a
Neuroprotection in Parkinson Disease Nicole Simpkins, BA; Joseph Jankovic, MD REVIEW ARTICLE Treatment of Parkinson disease has improved dramatically over the past quarter of a century and promising therapies
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationIntegrative approaches to Parkinson s Disease
Integrative approaches to Parkinson s Disease Brian Harris Kopell, M.D. C0-Director, Center for Neuromodulation Associate Professor Departments of Neurosurgery, Neurology, Psychiatry and Neuroscience An
More informationForm B3L: UPDRS Part III Motor Examination 1
Initial Visit Packet NACC Uniform Data Set (UDS) LBD MODULE Form B3L: UPDRS Part III Motor Examination 1 ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to
More informationParkinsons Disease & Movement Disorder Aug 11-13, Frankfurt l Dr. Geeta Shroff
USE OF HUMAN EMBRYONIC STEM CELLS IN THE TREATMENT OF PARKINSON S DISEASE Dr. Geeta Shroff Founder and Medical Director, Nutech Mediworld CONDITIONS TREATED Spinal Cord Injury Cell Culture Technology Diabetes
More informationKinematic Modeling in Parkinson s Disease
Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing
More informationFree Radicals in Biology and Medicine
Free Radicals in Biology and Medicine 0 \ Second Edition BARRY HALLIWELL Professor of Medical Biochemistry, University of London King's College and JOHN M.C. GUTTERIDGE Senior Scientist, National Institute
More informationIron Chelates and Unwanted Biological Oxidations
The Virtual Free Radical School Iron Chelates and Unwanted Biological Oxidations Kevin D. Welch and Steven D. Aust Department of Chemistry and Biochemistry Biotechnology Center Utah State University Logan,
More informationThe Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone
The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.
More informationAntioxidant Products
Antioxidant Products Introduction Introduction Antioxidant Total Antioxidant Status (TAS) Ransel Ransod Glutathione Reductase Antioxidants help defend living organisms against free radical attack. Many
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationSuperoxide Dismutase Kit
Superoxide Dismutase Kit Catalog Number: 7500-100-K Reagent kit for the analysis of Superoxide Dismutase in cell extracts. Sufficient reagents for 100 experimental tests, 50 negative controls, and 50 positive
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationKeywords: deep brain stimulation; subthalamic nucleus, subjective visual vertical, adverse reaction
Re: Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation Norbert Kovacs 1*, Jozsef Janszky 1, Ferenc
More informationRotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research
Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationCh. 4: Movement Disorders
Ch. 4: Movement Disorders Hiral Shah, MD Parkinson s Disease and DOPA Cotzias GC, Van Woert MH, and Schiffer, LM. Aromatic Amino Acids and Modification of Parkinsonism. N Engl J Med 1967; 276: 374-379.
More informationFree Fatty Acid Assay Kit (Fluorometric)
Product Manual Free Fatty Acid Assay Kit (Fluorometric) Catalog Number STA-619 100 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Triglycerides (TAG) are a type of lipid
More informationPh D THESIS ABSTRACT
ALEXANDRU IOAN CUZA UNIVERSITY IAŞI FACULTY OF BIOLOGY THE STUDY OF CHANGES FOR SEVERAL BIOCHEMICAL PARAMETERS OF OXIDATIVE STRESS IN ANIMAL MODELS FOR NEUROPSYCHIATRIC DISORDERS Ph D THESIS ABSTRACT Scientific
More informationmetabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine
6XPPDU\ Parkinson s disease is a serious neurological disorder of the central nervous system that usually becomes apparent after the age of 55. It concerns the increased deterioration of neurons responsible
More informationHT Glutathione Assay Kit
Instructions For Research Use Only. Not For Use In Diagnostic Procedures HT Glutathione Assay Kit Colorimetric assay for total, reduced and oxidized glutathione. Sufficient reagents for tests. Table of
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationMouse Hydrogen Peroxide (H2O2) Fluorescent Detection Kit
Mouse Hydrogen Peroxide (H2O2) Fluorescent Detection Kit CATALOG NO: IRAAKT2552 LOT NO: SAMPLE INTENDED USE The Hydrogen Peroxide Fluorescent Detection Kit is designed to quantitatively measure H2O2 in
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationParkinson s disease (PD) is a common neurodegenerative
: when should you initiate treatment? A range of effective drug treatments are available for (PD). However, long-term treatment is associated with the development of motor complications in a proportion
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationRelation between Lipid Profile and Total Antioxidant Status among Normal Population
Relation between Lipid Profile and Total Antioxidant Status among Normal Population N. Gupta *, P. Khadka, S. Yadav Department of Biochemistry, Universal Science College, Pokhara University, Kathmandu,
More informationLOOKING FOR LIPID PEROXIDATION IN VITRO AND IN VIVO: IS SEEING BELIEVING? Vanderbilt University School of Medicine Jason D.
LOOKING FOR LIPID PEROXIDATION IN VITRO AND IN VIVO: IS SEEING BELIEVING? Vanderbilt University School of Medicine Jason D. Morrow MD Which of the following assays of lipid peroxidation may be useful and
More informationHuman Hydrogen Peroxide Fluorescent Detection Kit
Human Hydrogen Peroxide Fluorescent Detection Kit CATALOG NO: IRAAKT2525 LOT NO: SAMPLE INTENDED USE The Hydrogen Peroxide Fluorescent Detection Kit is designed to quantitatively measure H₂O₂ in a variety
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationImaging biomarkers for Parkinson s disease
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson
More informationDARU Volume 13, No. 1,
DARU Volume 13, No. 1, 2005 23 COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON ALIJAN AHMADI AHANGAR, ALI REZA SADRAIE, SEYED BEHNAM ASHRAF VAGHEFI, MIR SAID RAMESANI Department
More informationMembrane lipid peroxidation by ultrasound: Mechanism and implications
J. Biosci., Vol. 15, Number 3, September 1990, pp. 211 215. Printed in India. Membrane lipid peroxidation by ultrasound: Mechanism and implications A. K. JANA, S. AGARWAL and S. N. CHATTERJEE* Biophysics
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationY. Hong 1, S. Hong 1, Y. H. Chang 1, S. H. Cho 2. Republic of Korea,
INFLUENCE OF AN ORALLY EFFECTIVE SUPEROXIDE DISMUTASE (GLISODIN ) ON STRENUOUS EXERCISE-INDUCED CHANGES OF BLOOD ANTIOXIDANT ENZYMES AND PLASMA LACTATE Y. Hong 1, S. Hong 1, Y. H. Chang 1, S. H. Cho 2
More informationParkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute
Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years
More informationFactors Affecting Oxidative Stability of Pork, Beef, and Chicken Meat
Animal Industry Report AS 654 ASL R2257 2008 Factors Affecting Oxidative Stability of Pork, Beef, and Chicken Meat Byung R. Min Ki C. Nam Joseph C. Cordray Dong U. Ahn, duahn@iastate.edu Recommended Citation
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationBasal ganglia motor circuit
Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationTHE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT
Jundishapur Journal of Natural Pharmaceutical Products 7; (): 8- Jundishapur Journal of Natural Pharmaceutical Products THE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT
More informationCholine Assay Kit (Fluorometric)
Product Manual Choline Assay Kit (Fluorometric) Catalog Number MET- 5042 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Choline is a water soluble amine that is an essential
More informationKEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?
KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's
More informationReactive Oxygen species ROS + Anti-oxidants. Dr. Naif Karadsheh
Reactive Oxygen species ROS + Anti-oxidants Dr. Naif Karadsheh Oxygen Toxicity & Free Radicals Biradical O 2 Radical O 2 Non-Radical Radical H 2 O 2 OH ROS O 2 Metabolism and Toxicity O 2 Consumption >90%
More informationLipid Oxidation and its Implications to Food Quality and Human Health. Dong Uk Ahn Animal Science Department Iowa State University
Lipid Oxidation and its Implications to Food Quality and Human Health Dong Uk Ahn Animal Science Department Iowa State University Introduction Process of Lipid Oxidation Free Radicals and Reactive Oxygen
More informationFluoro: MAO TM. Monoamine Oxidase A & B Detection Kit. Contact Information. This version to be used for kits shipped on or after April 27 th 2006
Fluoro: MAO TM Monoamine Oxidase A & B Detection Kit This version to be used for kits shipped on or after April 27 th 2006 Contact Information Notes Revised protocol 5/06 Updated 1/07 I. Assay Principle:
More informationCase Report Hyperechogenicity of the Substantia Nigra in Parkinson s Disease: Insights from Two Brothers with Markedly Different Disease Durations
Hindawi Case Reports in Neurological Medicine Volume 2017, Article ID 3673159, 4 pages https://doi.org/10.1155/2017/3673159 Case Report Hyperechogenicity of the Substantia Nigra in Parkinson s Disease:
More informationPlasma level of nitrates in patients with Parkinson s disease in West Bengal
Neurology Asia 2010; 15(1) : 55 59 Plasma level of nitrates in patients with Parkinson s disease in West Bengal 1 Jaya Sanyal, 1 BN Sarkar, 2 Tapas Kumar Banerjee, 3 Subhash Chandra Mukherjee, 4 Bidhan
More informationKen Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe and Yasuo Iwasaki. Abstract
ORIGINAL ARTICLE Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson s Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists Ken Ikeda,
More informationCatecholamines and neurotransmitter. Comprehensive tools for routine and research
Catecholamines and neurotransmitter diagnostics Comprehensive tools for routine and research Neurotransmitters in human and animals Catecholamines and neurotransmitters play essential roles in both humans
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationThis student paper was written as an assignment in the graduate course
77:222 Spring 2005 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2005) offered
More informationOriginal Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III
2004 97-106 Original Articles 1 2 3 1 1 2 3 47 22 III I II muscular rigidity postural disturbance resting tremor bradykinesia Calne, 2001 Mortimer, Pirozzolo, Hansch, & Webster, 1982 Tel: 02-23627076 E-mail:
More informationNon-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative
Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research
More informationMeasuring symptom change in patients with Parkinson s disease
Age and Ageing 2000; 29: 41 45 2000, British Geriatrics Society Measuring symptom change in patients with Parkinson s disease JOHN E. HARRISON, SARAH PRESTON 1,STAVIA B. BLUNT 1 CeNeS Ltd, Compass House,
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More information